6/2/2020 8:10:45 AM
Caladrius To Present On CLBS119 For COVID-19 Induced Lung Damage At BioNJ COVID-19 Rapid Fire Research Showcase
5/26/2020 8:05:11 AM
Caladrius Biosciences Announces $4.3 Mln Direct Offering
4/22/2020 8:06:00 AM
Caladrius To Get $10.9 Mln Of Non-Dilutive Capital Through NJEDA' Technology Business Tax Certificate Transfer Program
7/15/2019 8:40:44 AM
Caladrius Biosciences Says EMA Grants Advanced Therapy Medicinal Product Classification For CLBS12
6/4/2019 8:38:17 AM
Caladrius Biosciences Completes Enrollment In Phase 2 ESCaPE-CMD Trial For Coronary Microvascular Dysfunction
5/14/2019 6:43:19 AM
WBB Securities Starts Caladrius Biosciences, Inc. (CLBS) At Speculative Buy With $6.75 Price Target
11/8/2018 8:32:16 AM
Caladrius Biosciences Appoints Cynthia Schwalm To Board
6/19/2018 8:04:25 AM
Caladrius Gets FDA Regenerative Medicine Advanced Therapy Designation For CD34+ Cell Therapy For Refractory Angina
5/10/2018 4:09:52 PM
Caladrius Biosciences Q1 Net Loss From Cont Ops $5.0 Mln Or $0.52 Per Share
4/10/2018 8:04:22 AM
Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation In Japan For CLBS12 For Critical Limb Ischemia
3/22/2018 4:08:37 PM
Caladrius Biosciences Q4 Loss/share $0.29 Vs. Loss $0.73 Year Ago
3/13/2018 8:04:54 AM
Caladrius Biosciences Doses First Patient With CLBS12 In Phase 2 Critical Limb Ischemia Trial In Japan